Wplyw enrofloksacyny na przeciwdrgawkowe dzialanie diazepamu

• Autorzy: Wlaz P , Rolinski Z.
• Języki publikacji: PL

Abstrakty

EN

Enrofloxacin, a fluoroquinolone derivative exhibiting a broad spectrum of antibacterial activity, is known to induce several adverse neurologic side effects, such as psychomotor excitation, restlessness in animals, and hallucinations in humans. These side effects are probably attributable to the impaired GABA-ergic neurotransmission. This prompted us to study the effects of acute administration of enrofloxacin upon the antiepileptic efficacy of diazepam, an agent acting through an enhancement of GABA-ergic transmission, in maximal elektroshock-induced seizures in mice. All drugs were injected intraperitoneally at a volume of 10 ml/kg 60 min prior to the seizure test. A convulsive response, expressed as CC50 (defined by the lowest current intensity (in mA) necessary to produce the tonic hindlimb extension) was then determined. Enrofloxacin given alone in a dose of 50 mg/kg did not affect the seizure threshold as compared to the value abtained following saline treatment (11.6 mA and 12.0 mA, respectively). Administration of diazepam at a dose of 10 mg/kg resulted in a significant elevation of the seizure threshold, which reached 42.2 mA (p<0.05 versus saline- or enrofloxacin-treated animals). However, when mice were given a combination of both drugs, the protective activity of diazepam was diminished, which was reflected by a significant decrease in the convulsive current (21.7 mA; p<0.05 versus diazepam-treated mice). These data strongly suggest that the anticonvulsant properties of diazepam are reversed by concomitant treatment with enrofloxacin. Moreover, this might argue against the use of such antimicrobial agents in animals suffering from different types of seizure disorders.

Słowa kluczowe

PL

dzialanie antagonistyczne; leki weterynaryjne; enrofloksacyna; farmakologia; diazepam

• Wydawca: -
• Czasopismo: Medycyna Weterynaryjna
• Rocznik: 1995
• Tom: 51
• Numer: 10
• Opis fizyczny: s.596-597,tab.,bibliogr.

Twórcy

autor

Wlaz P

• Akademia Rolnicza, ul. Akademicka 12, 20-033 Lublin

autor

Rolinski Z.

Bibliografia

• 1. Akaike N., Hattori K., Inomata N., Oomura Y.: J. Physiol. (Londyn) 360, 367, 1985.
• 2. Akaike N., Shirasaki T., Yakashiji T. : J. Neurophysiol. 66, 497, 1991.
• 3. Ball P.: Clin. Inv. Med. 12, 28, 1989.
• 4. Gibaldi M.: Biopharmaceutics and clinical pharmacokinetics. Lea and Febiger, Philadelphia, 1984.
• 5. Haefely W., Kulscar A., Mdhler H., Piere L, Pole P., Schaffner R.: Adv. Biochem. Psychopharmacol. 14, 131, 1975.
• 6. Litchfield J. T., Wilcoxon F.: J. Pharmacol. Exp. Ther. 96, 99, 1949.
• 7. Loscher W.: GABA and the epilepsies. Experimental and clinical considerations. W: GABA: basic research and clinical applications., red Bowery N. G. i Nistico G., Pythagora Press, Rome, 1989.
• 8. Neumann M.: Clin. Pharmacokin. 14, 96, 1988.
• 9. Stiibner G., Weinrich IV., Bramds U.: Infection 14 (Suppl. 4), 250, 1986.
• 10. Thiébot M. H., Kłoczko J., Chermat R., Simon P., Soubrié P., Psychopharmacology 67, 91, 1980.
• 11. Unseld E., Ziegler G., Gemeinliardt A., Janssen U., Klotz UBr. J. Clin. Pharmacol. 30. 63, 1990.
• 12. Zaudig M., V. Bose M., Weber M. M., Bremer D., Zieglgiinsberger W.: Pharmacopsychiatry 22, 11, 1989.